A team of researchers from the Benaroya Research Institute in Seattle published their findings on a cell group only present in people with allergies called Th2A cells.
An Introduction to Biologic Therapies for Your Patients
Biologic therapies are becoming more popular for patients with allergic and immunologic diseases. As they ask more questions, point them to the libraries in the Condition & Treatments section of aaaai.org and have them look for our new series of articles on biologic therapies written by AAAAI member Jonathan Corren, MD. The first article in the series is “An Introduction to Biologic Therapies” and it’s available in both English and Spanish. The next article will be coming soon.
What is the AAAAI doing to look out for you and the allergy/immunology (A/I) specialty? I’d like to use this space to describe several ongoing efforts. The first four are being spearheaded by the AAAAI’s Advocacy Committee while the final item involving Maintenance of Certification (MOC) is taking place at the Executive Committee level.
Our work to address proposed standards and regulations impacting in-office compounding of allergen extract for immunotherapy has by no means ended. We are still heavily involved in this issue.
In fact, Andrew W. Murphy, MD, FAAAAI, Chair of the AAAAI’s Office of Practice Management and Advocacy Committee member, was recently invited by the United States Pharmacopeia (USP) to represent A/I on a small work group of physicians representing specialties impacted by the proposed update to Chapter 797. The work group provided feedback for the development of definitions of “administration” of compounded substances and “urgent use.”